2601c paliperidone
Titre original de l'avis
Norway – Medical equipments, pharmaceuticals and personal care products – 2601c paliperidone
Score d'opportunité
Pourquoi ce score ?
Opportunité
30 / 100
Complexité
50 / 100
Facteurs de risque
The notice lacks estimated value, award criteria, and eligibility requirements. This makes it impossible to evaluate th...
All documents are in Norwegian, which may disadvantage non-Norwegian bidders.
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Informations clés
- Pouvoir adjudicateur
- SYKEHUSINNKJØP HF
- Pays
- Norvège
- CPV
- 33000000 - Medical equipments, pharmaceuticals and personal care products +1 autres
- Date limite
- Aug 25, 2026
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jan 2028
- Supply of the active ingredient paliperidone
- Framework agreement with the four regional health authorities in Norway
Afficher le résumé complet
This tender by Sykehusinnkjøp HF, on behalf of the four regional health authorities in Norway, seeks to establish a framework agreement for the supply of the active ingredient paliperidone. The procedure is open, and electronic submission is required. However, critical information such as estimated value, award criteria, and eligibility requirements is missing from the notice, making it difficult to assess the opportunity fully.
Risques
The notice lacks estimated value, award criteria, and eligibility requirements. This makes it impossible to evaluate th...
All documents are in Norwegian, which may disadvantage non-Norwegian bidders.
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Open procedure
- Place of performance: Norway
Administrative
- Electronic submission required
Les exigences peuvent être incomplètes.
Critères d'attribution
Lot 1
Acheteur
Localisation
VADSØ, NOR
Profil acheteur
Identifiant
916879067
Activité
Health
Lots (1)
LOT-0001
2601c paliperidone
Procurement of the active ingredient paliperidone for Norwegian health authorities. The framework agreement covers supplies over approximately 15 months (planned start November 2026, end January 2028).
Localisation
Durée
Catégorie
Critères d'attribution
Date limite
Détails des critères
The contracting authority for this competition is Sykehusinnkjøp HF, on behalf of the four regional health authorities in Norway: Helse Sør-Øst RHF, Helse Vest RHF, Helse Midt-Norway RHF and Helse Nord RHF. Sykehusinnkjøp HF is procuring the active ingredient paliperidone.
Codes CPV supplémentaires
Note sur la valeur
Afficher les données TED originales
Description TED originale
The contracting authority for this competition is Sykehusinnkjøp HF, on behalf of the four regional health authorities in Norway: Helse Sør-Øst RHF, Helse Vest RHF, Helse Midt-Norway RHF and Helse Nord RHF. Sykehusinnkjøp HF is procuring the active ingredient paliperidone.
Détails de la procédure
- Date de publication
- 24 Jun 2026
- Langues
- English, Norwegian
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 434619-2026
Documents (2)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
30 / 100
Complexité
50 / 100
Facteurs de risque
The notice lacks estimated value, award criteria, and eligibility requirements. This makes it impossible to evaluate th...
All documents are in Norwegian, which may disadvantage non-Norwegian bidders.
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications